Business
Mesoblast now expects to release Ryoncil ruling on Monday – Stockhead
Mesoblast is in a trading halt, but doesn’t expect to announce the FDA’s decision on Ryoncil until Monday Approval of the stem cell treatment to treat pediatric…
Link copied toclipboard
- Mesoblast is in a trading halt, but doesn’t expect to announce the FDA’s decision on Ryoncil until Monday
- Approval of the stem cell treatment to treat pediatric graft-versus-host disease would be transformative for the company
- A reason for the delay wasn’t given
Mesoblast (ASX:MSB) shareholders have a few more sleepless nights ahead of them.
The closely watched biotech went into a trading halt this morning in relation to the US Food and …
Continue Reading
